- Home
- Programs and Groups
- Shared Resources
- Faculty
- Clinical Trials
- Tumor Registry
- Education
- About DCI
Quick Links
Katherine Peters's Clinical Trials
Items 1 - 5 of 5
Clinical and Neurocognitive Outcomes in Long-term Survivors of Primary Glioblastoma Multiforme
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Effects of Low-Dose Naltrexone on Quality of Life in High-Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Functional and Neurocognitive Profile of Patients Receiving Bevacizumab Containing Treatment Regimens for Glioblastoma Multiforme
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
A Phase I/II Single-Arm Open-Label Multicenter Study of VB-111 in Patients with Recurrent Glioblastoma Multiforme (VB-111-122)
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: 919-684-5301
Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects with Recurrent Malignant Glioma
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: (919) 684-5301
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: (919) 684-5301
